Armando Santoro
YOU?
Author Swipe
View article: RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer Open
View article: Dual FLT3/PIM inhibitor dapolsertib (MEN1703) in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial
Dual FLT3/PIM inhibitor dapolsertib (MEN1703) in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial Open
View article: Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study
Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study Open
Background CheckMate 8KX was a phase I/II study investigating the pharmacokinetics and safety of subcutaneous (SC) nivolumab±recombinant human hyaluronidase PH20 (rHuPH20). Methods Patients with advanced solid tumors who were immune-checkp…
View article: Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions
Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions Open
Pleural Mesothelioma (PM) remains a challenging malignancy associated with asbestos exposure and characterized by poor prognosis. This review aims to consolidate recent findings on the efficacy of perioperative therapies encompassing chemo…
View article: Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory Primary Mediastinal B-Cell Lymphoma
Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory Primary Mediastinal B-Cell Lymphoma Open
Not available.
View article: Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge
Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge Open
View article: Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis
Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis Open
Eighty-two patients were eligible for allogeneic transplantation (Allo-SCT) at our Institution between April 2014 and August 2022. Of these, 72 actually received Allo-SCT, n = 44 after checkpoint inhibitor (CPI) containing salvage therapy …
View article: Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy
Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy Open
(1) Background: The presence of metastatic disease significantly increases the risk of venous thromboembolism (VTE) in breast cancer, particularly during chemotherapy. Although not categorized as a highly thrombogenic malignancy, the eleva…
View article: Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes Open
Summary Clinical outcome after chimeric antigen receptor (CAR)‐T‐cell failure in large B‐cell lymphoma (LBCL) is dismal. Allogeneic stem cell transplantation (alloSCT) represents a potentially curative salvage for relapsed/refractory LBCL,…
View article: Primary open-angle glaucoma
Primary open-angle glaucoma Open
Primary open-angle glaucoma (POAG) is a chronic and progressive optic neuropathy characterized by the degeneration of optic nerve fibers and gradual loss of the visual field. It is the most common form of glaucoma and one of the leading ca…
View article: MRI-based radiomics predicts the pathologic response of colorectal liver metastases to systemic therapy: A multicenter study
MRI-based radiomics predicts the pathologic response of colorectal liver metastases to systemic therapy: A multicenter study Open
The addition of radiomic features extracted from the PVP and HBP of post-chemotherapy Gd-EOB-DTPA-enhanced MRI enhanced standard radiologic and clinical assessment of CRLM response to chemotherapy, providing a reliable non-invasive assessm…
View article: Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset Open
View article: Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study Open
Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C –positive non–small cell lung…
View article: Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort
Using [18F]FDG PET/CT to Identify Optimal Responders to Neoadjuvant Therapy in Breast Cancer—Results from a Prospective Patient Cohort Open
Background/objectives: Pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is a solid indicator of favourable prognosis, potentially also being useful for more conservative patient management. We ai…
View article: Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy Open
ClinicalTrials.gov, NCT02684292.
View article: 461 | OUTCOMES OF CAR T‐CELL THERAPY IN TRANSFORMED INDOLENT NON‐HODGKIN LYMPHOMAS AND DE NOVO DLBCL: A COMPARATIVE ANALYSIS FROM THE ITALIAN CAR T‐SIE STUDY
461 | OUTCOMES OF CAR T‐CELL THERAPY IN TRANSFORMED INDOLENT NON‐HODGKIN LYMPHOMAS AND DE NOVO DLBCL: A COMPARATIVE ANALYSIS FROM THE ITALIAN CAR T‐SIE STUDY Open
View article: 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY
280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY Open
View article: 51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY
51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY Open
View article: 57 | CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL
57 | CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL Open
View article: Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy
Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy Open
Background CDK4/6 inhibitors (CDK4/6i) are cornerstone therapies in Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) Breast Cancer (BC) and emerging evidence suggests that they may influence immune …
View article: A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA Open
This study analyzed the genetics of classic Hodgkin lymphoma (cHL) by using circulating tumor DNA (ctDNA). Two genetic subtypes were identified, differing in genetic instability mechanisms: one subtype (64% of cases) showed a higher mutati…
View article: Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia Open
View article: Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions
Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions Open
Primary and secondary brain tumors have always been a challenge due to their high morbidity and poor prognosis. The incidence of brain metastasis is also increasing with the advent of effective new treatments. Traditional systemic treatmen…
View article: Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes Open
PURPOSE Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical…
View article: 389P Real-world feasibility, safety and treatment outcomes of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in elderly breast cancer patients
389P Real-world feasibility, safety and treatment outcomes of Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in elderly breast cancer patients Open
View article: Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial Open
View article: Erratum: Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial
Erratum: Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial Open
View article: Assessment of the Mechanisms of Action of Eribulin in Patients with Advanced Liposarcoma Through the Evaluation of Radiological, Functional, and Tissue Responses: A Prospective Monocentric Study (Malibu Study)
Assessment of the Mechanisms of Action of Eribulin in Patients with Advanced Liposarcoma Through the Evaluation of Radiological, Functional, and Tissue Responses: A Prospective Monocentric Study (Malibu Study) Open
Background: Liposarcoma (LPS) is one of the most frequent histotypes of soft tissue sarcoma (STS). Eribulin is a cytotoxic agent that has improved overall survival in patients with advanced LPS. Additionally, preclinical and clinical evide…
View article: Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis After Peripheral Blood Stem Cell HLA Identical Transplantation in Patients with Lymphoma: A Prospective Observational Study
Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis After Peripheral Blood Stem Cell HLA Identical Transplantation in Patients with Lymphoma: A Prospective Observational Study Open
Allogeneic stem cell transplantation (allo-SCT) from HLA-identical donors (HLAid) could be an effective salvage treatment for relapsed/refractory lymphoma. In this setting, standard graft-versus-host disease (GVHD) prophylaxis is based on …
View article: Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events Open
Immune checkpoint inhibitors (ICIs) revolutionized cancer therapy, yet require management of immune-related adverse events (irAEs). Fulminant myocarditis is a rare irAE, but lower-severity cardiac events are being reported more frequently,…